Life Technologies

Kodiak focuses on companies in the areas of life sciences tools, diagnostics and medical devices. We seek opportunities where we can apply our broad experience in technology to help entrepreneurs bring high-impact solutions to market.

ALIS Logo
ALIS was acquired by Carl Zeiss SMT in July 2006.
Kodiak Partner: Dave Furneaux

 
Allegro Diagnostics, Inc Logo

Allegro Diagnostics was acquired by Veracyte in September 2014.


Kodiak Partner: Andrey Zarur

 
Fluxion Biosciences Logo

Fluxion Biosciences develops high-throughput cell biology platforms that address critical bottlenecks in the discovery and development of new treatments for cancer, heart disease, immune disorders, and other major illnesses. Fluxion's breakthrough microfluidics technology utilizes the precision and scalability of silicon wafer fabrication to produce systems with a level of throughput and cost-effectiveness unattainable with conventional research approaches.

www.fluxionbio.com/


Kodiak Partner: Dave Furneaux

 
GreenLight Biosciences Logo

GreenLight Biosciences is a biotechnology company focused on sustainable production of chemicals and fuels using its Unconstrained MetabolismTM technology platform. This revolutionary technology enables the biological conversion of economical, renewable substrates to valuable products with unprecedented flexibility and control. GreenLight is able to deliver an attractive solution for production of chemicals and fuels from renewable resources, eliminating the need for petroleum feedstock or expensive natural precursors.

http://www.greenlightbiosciences.com/


Kodiak Partner: Dave Furneaux

 
Lumicell Logo


Lumicell is developing a device that will enable surgeons to check the tumor site immediately following surgery for remaining cancer cells after removing the tumor. The technology consists of a proprietary detector and initially a commercial available molecule marker. The detector along with a dye that is injected into the site will radiate fluorescent light when coming into contact with a cancer enzyme, allowing the surgeon to remove the remaining cancer cells. The technology must be capable of detecting a small number of cancer cells (1-100) left behind. The detector will have a disposable tip for each patient and reagents that will be the basis of the reimbursement and Lumicell revenue along with the initial sales of the instrument.

http://lumicell.com


Kodiak Partner: Dave Furneaux